"Clinical benefit" following treatment with antineoplastic drugs: what does it mean and how should we measure it?

Markman M

Curr Oncol Rep. 1999 Sep;1(1):1-2. doi: 10.1007/s11912-999-0001-y.

Abstract

摘要

相似文献

Curr Oncol Rep. 1999 Sep;1(1):1-2. doi: 10.1007/s11912-999-0001-y.

Postgrad Med. 2013 Mar;125(2):83-91. doi: 10.3810/pgm.2013.03.2643.

Gan To Kagaku Ryoho. 1994 Oct;21 Suppl 3:333-7.

J Cancer Res Clin Oncol. 1994;120(10):569-70. doi: 10.1007/BF01212809.

Stat Med. 1994;13(13-14):1293-5. doi: 10.1002/sim.4780131303.

Int J Oncol. 2001 Nov;19(5):1075-80. doi: 10.3892/ijo.19.5.1075.

Suppl Tumori. 2004 Jul-Aug;3(4):S48-9.

Important Adv Oncol. 1992:235-41.

Int J Gynecol Cancer. 2010 Oct;20(11 Suppl 2):S60-3. doi: 10.1111/IGC.0b013e3181f60af6.

Suppl Tumori. 2004 Jul-Aug;3(4):S50-1.

20分钟写一篇综述，助力文献阅读效率提升50倍。

大模型驱动的PubMed中文搜索引擎

学术文献翻译模型，支持多种主流文档格式。